Granules India Ltd.
http://www.granulesindia.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Granules India Ltd.
India’s Interim Budget Pushes Innovation, Green Production, HPV Vaccination
India’s interim budget 2024 hikes allocation for production-linked incentive schemes in pharmaceuticals, supports biotech start-ups - particularly green ones- and sets the right note for inclusion of HPV vaccination in the country’s Universal Immunization Program, one of the world's largest public health programs. How does it help?
Ajinomoto Builds Gene Therapy CDMO Capabilities Through $554m Forge Acquisition
With an ambitious growth plan for its CDMO operations, Ajinomoto is planning to complete the acquisition of Forge Biologics Holdings by December, adding the US-based firm’s capabilities in gene therapy services.
Quality Street: India Needs A Frances Kelsey, Many Of Her Kind
Scrip delves into some of India’s critical compliance and quality challenges and efforts to address those.
A Year Of Paxlovid - Where Is The Licensed Generic?
A year since Paxlovid was launched and The Medicines Patent Pool licensed Pfizer’s nirmatrelvir, we look at a few likely reasons for authorized generics of Paxlovid not turning up and what lies ahead in 2023, as Hetero’s version becomes the first with WHO prequalification while two Chinese and a Korean company wait in the wings.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Services
- Contract Manufacturing Organization
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice